Supriya Lifescience Targets Rs 1,600-Crore Revenue In 3 Years; Details Here

Supriya Lifescience, which is expanding its operations, is targeting up to Rs 1,600 crore in revenue from its Lote MIDC in Ratnagiri and Ambernath facilities over the next three years, according to a top

company executive. We had revenue of Rs 706 crore in 2024-25, and expect 20 percent growth in FY26.

With all the planned expansions, we expect a significant increase in revenue. In the next three years, we aim to reach around Rs 1,600 crore from our existing Lote Maharashtra Industrial Development Corporation and Ambernath facility, which should start contributing to revenue from January-February 2026, said Supriya Lifescience MD Saloni Wagh.

She mentioned that the company’s Patalganga facility will take about 2.5 to 3 years to become operational. Our main growth drivers will be new products and existing products that currently have zero market share. Every year, we plan to launch 3-4 products. We are also considering a major partnership for our CMO (contract manufacturing organisation) and CDMO (contract development and manufacturing organisation), she added.

Supriya Lifescience, which focuses on active pharmaceutical ingredients (APIs), invested Rs 160 crore to set up its Ambernath facility and Rs 350 crore for the Patalganga unit, which will be spent in phases, Wagh said. We are a debt-free company and all capital expenditure is funded through internal accruals, she added. She said the company is increasingly positioning itself as a niche player in complex, chemistry-driven APIs, moving away from mass-market commoditised products.

This strategy is helping the company grow despite ongoing volatility in the global API industry, such as currency fluctuations and regulatory changes. Instead of chasing scale in crowded markets, we are strengthening our position as a specialised supplier, focusing on fewer molecules and markets, and building deeper relationships with our global customers, she added.

Supriya Lifescience’s business is mainly export-driven, with 84 percent of revenue coming from international markets. Europe is the largest contributor at 40 percent, followed by Latin America at 22 percent, with Asia and the Middle East making up the rest. India contributes only 14 percent, mostly from multinationals serving regulated markets. The company’s direct exposure to the US remains below 5 percent, reflecting its focus on markets where complexity is more important than price competition.

Supriya Lifescience has two research and development centers, Lote and Ambernath, with about 60 scientists working on API and formulation development. We spend about 1 percent of our revenue on R&D, which is expected to increase to 2 percent as our new programs grow, Wagh said. The company’s upcoming product pipeline includes liquid anaesthetics, cardiovascular intermediates, contrast media, and products focused on ADHD, she added.